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Abstract 
During limb development Pax3 positive myoblasts delaminate from the hypaxial 
dermomyotome of limb level somites and migrate into the limb bud where they form 
the dorsal and ventral muscle masses. Only then do they begin to differentiate and 
express markers of myogenic commitment and determination such as Myf5 and 
MyoD. However the signals regulating this process remain poorly characterised. We 
show that FGF18, which is expressed in the distal mesenchyme of the limb bud, 
induces premature expression of both Myf5 and MyoD and that blocking FGF 
signalling also inhibits endogenous MyoD expression. This expression is mediated by 
ERK MAP kinase but not PI3K signalling. We also show that retinoic acid (RA) can 
inhibit the myogenic activity of FGF18 and that blocking RA signalling allows 
premature induction of MyoD by FGF18 at HH19. We propose a model where 
interactions between FGF18 in the distal limb and retinoic acid in the proximal limb 
regulate the timing of myogenic gene expression during limb bud development. 
 
Introduction 
Amniote limb muscles are derived from myoblasts that originate in somites and 
migrate into developing limb buds (Chevallier et al., 1977; Christ and Brand-Saberi, 
2002). Delamination and migration of these cells from the ventro-lateral lip of the 
hypaxial dermomyotome is regulated by Hepatocyte Growth Factor / Scatter Factor 
(HGF/SF) (Dietrich et al., 1999; Scaal et al., 1999) and requires the paired box 
transcription factor Pax3 (Franz et al., 1993). Once in the limb myoblasts migrate to 
form the dorsal and ventral muscle masses. Only then do they begin to express the 
Myogenic Regulatory Factors (MRFs), basic helix loop helix transcription factors 
comprising Myf5, MyoD, myogenin and MRF4 which, ultimately, leads to 
differentiation of mature, functional myotubes (Buckingham et al., 2003; Mok and 
Sweetman, 2011). 
Myogenesis has been extensively studied during embryo development and provides 
an excellent paradigm to understand how inductive signals regulate differentiation. 
Much of this work has focused on somites and extensive work has shown that 
interactions between Wnt, Shh and BMP signalling in both chicken and mouse 
embryos are critical for myogenesis (Borycki et al., 1999; Borycki et al., 1998; 
Hirsinger et al., 1997; Munsterberg et al., 1995; Munsterberg and Lassar, 1995; 
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Pourquie et al., 1996; Tajbakhsh et al., 1998). However it is clear that the signalling 
events that control myogenesis in developing limbs are distinct from those in somites. 
It has been suggested that limb myoblasts differentiate via a default pathway once 
they escape inhibitory BMP (Amthor et al., 1998). Nevertheless other signals are 
involved in limb myogenesis (Christ and Brand-Saberi, 2002; Duprez, 2002; Venters 
et al., 2004) including Fibroblast Growth Factors (FGFs) (Edom-Vovard et al., 2001; 
Marics et al., 2002) and retinoic acid (RA) (Reijntjes et al., 2010) both of which have 
been reported to have inductive and repressive roles depending on concentration 
and cellular context. Recently Shh has also been shown to have an important role in 
the initiation of Myf5 and MyoD expression in limb myoblasts as well as their 
subsequent migration (Anderson et al., 2012; Hu et al., 2012). 
Several lines of evidence suggest that FGF receptors play important roles in limb 
myogenesis (Flanagan-Steet et al., 2000; Lagha et al., 2008; Marcelle et al., 1995; 
Marics et al., 2002). Grafting of FGF soaked beads has been shown to negatively 
regulate muscle cell differentiation in somites (Sweetman et al., 2006) while retroviral 
FGF4 mediated expression can inhibit myogenesis in limbs (Edom-Vovard et al., 
2001). However it has not been clearly established which of the FGF ligands are 
responsible for this activity in vivo and is further complicated by the ability of FGFs to 
induce their own negative regulators, resulting in complex feedback loops (Eblaghie 
et al., 2003; Smith et al., 2005). Although ectopic FGF4 can inhibit limb bud muscle 
gene expression (Edom-Vovard et al., 2001) it is normally expressed in the apical 
ectodermal ridge (AER) which is probably too far from the developing myoblasts to 
play a role (Christen and Slack, 1999) while FGF10, which is expressed in the limb 
bud mesenchyme, is not able to induce myogenic gene expression in vivo (Ward et 
al., 2003). Other FGFs expressed in the limb include FGF8 and FGF2 which, like 
FGF4, are expressed in the AER, and FGF12 and FGF13 which are intracellular 
FGFs and do not signal via tyrosine kinase receptors (Karabagli et al., 2002). At least 
two FGF receptors, FGFR1 and FGFR4, are expressed in areas of the limb where 
myoblasts are located (Marcelle et al., 1995; Sheeba et al., 2010) and loss of 
function of either of these receptors disrupts limb muscle formation (Flanagan-Steet 
et al., 2000; Itoh et al., 1996; Marics et al., 2002). 
We wished to determine which FGF is likely to regulate limb bud myogenic gene 
expression in vivo. We identified FGF18 as a candidate because it is expressed in 
the limb bud mesenchyme (Maruoka et al., 1998; Ohuchi et al., 2000) and can signal 
through FGFR4 which is known to play a role in myogenesis (Kwiatkowski et al., 
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2008; Marics et al., 2002; Zhang et al., 2006). FGF18 has been shown to regulate 
chondrocyte proliferation and hence bone growth in the developing limb (Liu et al., 
2007) as well as hair follicle growth (Kawano et al., 2005; Leishman et al., 2013) and 
lung development (Elluru et al., 2009; Usui et al., 2004) but has not previously been 
implicated in myogenesis.  
Interactions between retinoic acid and FGF signals have also been proposed to 
pattern the proximal-distal axis of the developing chick limb (Cooper et al., 2011; 
Mercader et al., 2000; Rosell-Dez et al., 2014; Rosell-Dez et al., 2011). While this 
idea remains controversial (Cunningham et al., 2013) we hypothesised that 
interactions between these signals could provide a mechanism for controlling the 
timing of myoblast commitment and differentiation in the developing chicken limb. In 
this context it is worth noting that FGF and RA signalling pathways are known to 
interact during axis extension (del Corral et al., 2003) and that FGF18 expression is 
also regulated by RA signalling in both the trunk (Zhao and Duester, 2009) and the 
digits (Zhao et al., 2010). 
Our data suggest that FGF18 from the distal limb bud regulates the timing of 
expression of the myogenic markers Myf5 and MyoD through the ERK MAP kinase 
signalling pathway and that this is antagonised by high levels of retinoic acid in the 
proximal limb. We propose that interactions between these signalling pathways 
control the timing of progression of myoblasts from proliferative precursors to 
committed myocytes.  
 
Materials and Methods 
Probes and in situ hybridisation. 
Dig-11-UTP (Roche) labelled antisense RNA probes were generated from full length 
cDNAs for Myf5 and MyoD cloned into pGEM (Promega) (Sweetman et al., 2008) 
were linearised with SacII and transcribed with SP6 RNA polymerase. Myogenin 
probes were generated from pBS-SK-Mgn linearised with SalI and transcribed with 
T7 RNA polymerase. Full length FGF18 was cloned from whole D5 embryo cDNA 
into pGEM using the following primers: FGF18F: ATGTATTCACTGCTCTCC, 
FGF18-HA-R (also includes sequence for c terminal HA tag): 
TAAGCGTAATCTGGAACATCGTATGGGTAACTGGGGTTGGTGGGTCG. PCR was 
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performed with Phusion DNA polymerase (NEB), A-tailed and cloned into pGEM-T 
Easy. For Dig labeled probe transcription plasmid DNA was linearised with SacII and 
transcribed with SP6 RNA polymerase. MRF probes were as described in 
(Sweetman et al., 2008) and Pax3 probes as in (Abu-Elmagd et al., 2010). In situ 
hybridisation was as described in (Smith et al., 2005). 
Immunostaining. 
Embryos were harvested and dissected in cold PBS and fixed in 4% 
paraformaldehyde at 4¡C overnight. Embryos were then washed in PBS for 30 mins 
at room temperature and then washed in 0.2% Triton X-100 at 4¡C overnight. 
Embryos were washed in PBS for 30 mins at room temperature and then incubated 
in PBS with Mouse-anti p44/42 MAPK (Erk1/2) (Cell Signalling Technology, cat no 
9102,) diluted 1:50 in PBS at 4¡C for 72 hours in darkness. Embryos were then 
washed in PBS and incubated in PBS with Alexa Fluor 488 goat anti-mouse IgG2b 
(Invitrogen) diluted 1:200 at 4¡C overnight. Embryos were fixed and imaged on a 
Leica MZ10F steromicroscope. 
FGF and pharmacological inhibitor beads. 
Heparin beads (Sigma H-5263) were soaked for 1 hour at room temperature in 
recombinant FGF18, FGF4 or FGF10 (Peprotech) at 0.5mg/ml reconstituted in PBS 
with 0.1% BSA before grafting into limb buds. Control beads were soaked in PBS 
with 0.1% BSA for 1 hour. AG-1 X2 beads (BioRad) were incubated in either 4 mg/ml 
all-trans retinoic acid (Sigma) or the following pharmacological inhibitors: 10mM 
U0126 (Merck), 10 mM SB203580 (Tocris bioscience), 2 mg/ml BMS493 (Tocris), 
10mM LY294002 (Calbiochem), 10mM SU5402 (Calbiochem) or 10mM FIIN 1 
hydrochloride (Tocris bioscience) all dissolved in DMSO. Control beads were soaked 
in DMSO. Beads were soaked in inhibitors for at least 1 hour at room temperature in 
the dark, washed briefly in 2% phenol red then rinsed in PBS prior to grafting. 
Chick embryo manipulations. 
Fertile chicken White Leghorn eggs were obtained from Henry Stewart & Co Ltd 
(Norfolk, UK) and incubated at 37.5¡C until the desired Hamburger- Hamilton stage 
was reached. Manipulated embryos were visualised by injection of Windsor & 
Newton Black India Ink diluted 1:500 in PBS under the embryo. Beads were grafted 
into slits cut into limb buds with a sharpened tungsten wire needle. Eggs were re-
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sealed with sellotape and incubated at 37.5¡C for either 1, 6 or 24 hours. 
 
Results  
FGF18 expression in developing limb mesenchyme is consistent with a role in 
myogenic gene induction 
As FGF18 expression has been described in developing chicken and mouse embryo 
limbs (Maruoka et al., 1998; Ohuchi et al., 2000) we first confirmed that it is 
expressed in chick embryos with a spatio-temporal pattern consistent with a role in 
myogenesis. We cloned a full length FGF18 cDNA for in situ hybridisation and 
examined its expression from HH stage 18 to HH stage 26, the period when 
myoblasts migrate into and differentiate in limb buds. At HH18 FGF18 is expressed in 
the tailbud, pharyngeal arches, nasal placode and isthmus, consistent with previous 
reports (Fig.1A) (Ohuchi et al., 2000). We first detected FGF18 in limb buds at HH20 
where it is expressed in the distal mesenchyme of both fore- and hindlimbs (Fig.1B). 
Expression of FGF18 is maintained in the distal mesenchyme from stages HH22 to 
HH stage 26 (Fig.1C, D, E) and at HH26 is also detected in the condensing cartilage 
of the hind limb (Fig.1E). Sections through limb buds at HH22 show expression of 
FGF18 distal to the dorsal and ventral muscle masses where Pax3 expressing 
myoblasts are beginning to differentiate and express markers such as Myf5 and 
MyoD (Fig.1F, G, H, I). 
Grafting FGF18 beads into developing limbs induces premature expression of 
Myf5, MyoD and myogenin 
To test directly if FGF18 can induce expression of muscle markers we grafted beads 
soaked in recombinant FGF18 protein into developing limbs at stages between HH19 
and HH21 and analysed effects on myogenesis by in situ hybridisation with specific 
markers for different stages of muscle development. Ectopic expression of Myf5 in 
migratory myoblasts was detected after six hours incubation with FGF18 at HH19 
(6/6 embryos, Fig.2A, B, M) and HH21 (7/7 embryos, Fig.2G, H, N). MyoD is 
upregulated by FGF18 after six hours at HH stage 21 (12/12 embryos, Fig.2I, J) but 
not at HH stage 19 (12/12 embryos, Fig.2C, D). To assess the effects on later 
markers of myogenesis we also examined myogenin expression after FGF18 bead 
grafts at HH21. Six hours after grafting we did not detect ectopic myogenin 
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expression (4/4 embryos, Fig.2E, F) but did after 24 hours incubation with FGF18 
beads (5/6 embryos, Fig.2K, L). 
As Pax3 is expressed in proliferative myoblasts and downregulated as differentiation 
proceeds we also examined the effects of FGF18 on this gene. Although we did not 
observe large scale changes in expression in wholemount embryos with FGF18 
beads grafted at HH21 (4/4 embryos) (Fig.2O) sections through these limbs did show 
localised downregulation of Pax3 immediately adjacent to the FGF18 bead (Fig.2P) 
We also tested the ability of other FGFs to induce ectopic MyoD expression. FGF4 
was able to induce MyoD expression (9/9 embryos, Fig.2Q) while FGF10 was not 
(7/7 embryos, Fig.2R). 
Embryos grafted with control beads soaked in 0.1% BSA did not show ectopic 
expression of Myf5 at HH19 (4/4 embryos, Fig.1S, T) or HH21 (5/5 embryos Fig2U, 
V). We also did not detect ectopic MyoD expression following 0.1% BSA bead grafts 
at HH19 (5/5 embryos, data not shown) or after grafting at HH21 (6/6 embryos, 
Fig.1W, X). 
FGF18 dependant MyoD expression requires ERK phosphorylation 
To identify the signal transduction pathway responsible for ectopic MyoD expression 
following FGF18 bead application we used a phospho specific antibody staining to 
detect activiation of ERK MAP kinase. Within 1 hour of bead grafting we detected 
high levels of phospho-ERK in the mesenchyme surrounding the bead (3/3 embryos, 
Fig.3A-C). Beads soaked in FGF10 (4/4 embryos, Fig.3D-F), which is also expressed 
in limb bud mesenchyme but has different receptor specificity (Zhang et al., 2006), or 
control beads soaked in 0.1% BSA (4/4 embryos, Fig.3G-I) did not induce ERK 
phosphorylation. 
To confirm that these results were specific to FGF receptor activation and not off 
target effects from FGF beads we co-grafted FGF18 beads with beads soaked in an 
inhibitor of all four FGFRs, FIIN 1 hydrochloride, which was able to block FGF18 
induced MyoD expression (18/19 embryos, Fig.4A). We also tested SU5402, another 
FGFR inhibitor which blocks signalling from FGFR1 and FGFR3, but this did not 
prevent FGF18 induced MyoD expression (8/10 embryos, Fig.4D). 
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As MEK is upstream of ERK and is responsible for its phosphorylation we tested if its 
activity was required for ectopic MyoD expression induced by FGF18 by grafting 
FGF18 and beads soaked in the MEK inhibitor U0126 adjacent to each other in 
developing limb buds for 6 hours. In these embryos U0126 beads blocked FGF18 
induced expression of MyoD (12/13 embryos, Fig.4B). To confirm the specificity of 
MEK in blocking FGF18 induced MyoD expression we also co-grafted FGF18 and 
beads soaked in the PI3K inhibitor LY294002. In these embryos FGF18 was still able 
to induce MyoD expression in the presence of LY294002 (8/11 embryos, Fig.4C). 
Control beads soaked in DMSO did not affect MyoD induction by FGF18 (6/6 
embryos, Fig.4E). 
To test if inhibition of MEK could also block endogenous expression of MyoD we 
grafted U0126 beads into embryos at HH23, the point at which MyoD expression is 
first detected in limb buds by in situ hybridisation. U0126 grafted limbs had reduced 
MyoD expression when compared to contralateral unmanipulated limbs (8/10 
embryos Fig.4F, G) while DMSO control beads did not (10/10 embryos Fig.4H, I). 
We then grafted beads soaked in either FIIN 1 hydrochloride, U0126 or DMSO into 
limb buds at HH21, harvested them after 24h and examined MyoD expression by 
comparing operated limb buds to contralateral controls. FIIN 1 hydrochloride beads 
abrogated MyoD expression, particularly in the dorsal muscle mass (9/11 embryos, 
Fig.4J, K) while U0126 beads did not affect MyoD expression in the majority of cases 
(17/24 embryos, Fig4.L, M) although localised MyoD downregulation was observed in 
some cases (7/24 embryos). Control embryos with DMSO beads had normal MyoD 
expression in most cases (15/19 embryos, Fig.4N, O) 
Retinoic acid prevents FGF18 induced MyoD expression while RA inhibitors 
potentiate it. 
Retinoic acid is known to have both positive and negative effects on limb muscle 
differentiation depending on concentration (Reijntjes et al., 2010) and it has also 
been suggested that interactions between retinoic acid and FGF signalling can 
influence proximal-distal limb patterning (Cooper et al., 2011; Mercader et al., 2000; 
Rosell-Dez et al., 2011). Therefore we tested if RA signalling could affect the ability 
of FGF18 to induce myogenic gene expression. All trans retinoic acid (ATRA) soaked 
beads were grafted into forelimbs at HH21 and embryos harvested after 24h. MyoD 
expression was reduced in these forelimbs compared to contralateral limbs (9/9 
embryos, Fig.5A, B), consistent with previous reports (Reijntjes et al., 2010). We then 
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tested the ability of ATRA to block FGF18 induced MyoD expression directly by 
grafting FGF18 soaked beads adjacent to ATRA soaked beads into HH21 limb buds. 
The majority of these embryos did not show ectopic MyoD expression (19/25 
embryos, Fig.5C, D). Control embryos grafted with FGF18 and beads soaked in 
DMSO at HH21 showed the expected induction of MyoD (6/6 embryos, Fig.4D). We 
grafted beads soaked in BMS493, a retinoic acid antagonist, into HH19 embryos 
along with FGF18 soaked beads. In these embryos we saw ectopic expression of 
MyoD (8/9 embryos, Fig.5E, F) in contrast to embryos grafted with FGF18 alone at 
HH19 which do not express ectopic MyoD (Fig.2D). Beads grafted into HH19 
forelimbs soaked in BMS493 did not induce MyoD expression after 6h (10/10 




Our results show that FGF18 in limb buds can induce expression of the key 
regulators of myogenesis, Myf5 and MyoD within 6 hours of bead grafting, and that 
this is mediated via ERK MAP kinase signalling. We also demonstrate differing 
temporal responses in that Myf5 is induced in both early (HH19) and later (HH21) 
limb buds while MyoD expression is only induced at later stages (HH21+). Finally we 
show that ectopically applied retinoic acid can inhibit the ability of FGF18 to induce 
MyoD while a retinoic acid antagonist, BMS493, can potentiate it in early limb buds. 
We propose that interactions between these two signals regulate the timing of onset 
of Myf5 and MyoD expression in limb myoblasts (Fig.6A, B). 
FGF18 induces myogenic gene expression 
Signals inducing myogenic expression have been extensively studied in somites and 
both Myf5 and MyoD are known to be induced by Wnt and Shh signalling in the 
epaxial myotome (Borycki et al., 1998; Munsterberg et al., 1995; Tajbakhsh et al., 
1998) and by Wnt and BMP in the hypaxial myotome (Dietrich et al., 1998; Geetha-
Loganathan et al., 2005; Marcelle et al., 1997). In developing limbs the inductive 
signals are much less well characterised although several factors have been shown 
to inhibit early myogenesis including HGF/SF (Scaal et al., 1999), retinoic acid 
(Reijntjes et al., 2010), BMPs (Amthor et al., 1998) Shh (Duprez et al., 1998) and 
Notch (Delfini et al., 2000; Mayeuf-Louchart et al., 2014) while other factors known to 
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induce early myogenic gene expression in somites, such as Wnts and Shh, appear to 
regulate later stages of limb muscle development (Anakwe et al., 2003; Anderson et 
al., 2012; Hu et al., 2012). As a result it has been proposed that limb bud myoblasts 
undergo differentiation as a result of the withdrawal of inhibitors of differentiation 
rather than in response to inductive signals (Amthor et al., 1998). 
A strong candidate for an inducer of myogenic genes in developing limbs is FGF 
signalling through FGFR4. FGFR4 is required during myogenic differentiation of 
C2C12 cells (Kwiatkowski et al., 2008), is expressed in myoblasts as they migrate 
into the limb (Sheeba et al., 2010) and a dominant negative form of this receptor can 
inhibit Myf5, MyoD and MHC expression in limb myoblasts during development 
(Marics et al., 2002). Our data are consistent with a role for FGFR4 as both FGF18 
induced and endogenous MyoD expression was blocked by a pan-FGFR inhibitor 
(FIIN 1 hydrochloride) (Zhou et al., 2010) but not SU5402 which is known to block 
FGFR1 and 3 (Grand et al., 2004; Mohammadi et al., 1997) but has not been shown 
to directly affect FGFR4 activity. 
However it has not been established which of the FGFs mediates this activity. Our 
data show that FGF4 or FGF8 soaked beads can induce MyoD in developing limbs in 
the same way as FGF18 (Fig.2 and data not shown) but these FGFs are normally 
restricted to the Apical Ectodermal Ridge, some distance from the differentiating 
myoblasts. Although FGFs can act over several cell diameters (Christen and Slack, 
1999) the AER is probably too far from the myoblasts to be the source of an inductive 
signal for these cells and ERK phosphorylation in response to ridge FGFs does not 
seem to extend into the myogenic regions of the limb bud (Corson et al., 2003). In 
contrast to our data, previous reports have shown that FGF4 in limb buds can lead to 
loss of myogenic gene expression (Edom-Vovard et al., 2001); we believe that this 
can be reconciled with our observations as the manipulations we performed were 
different in two important respects; our observations were carried out over very short 
time scales, making it likely that this conflicting data was uncovering a later function 
of FGF signalling, and we used bead grafts to deliver FGF while Edom-Vovard et al 
used RCAS retroviral misexpression. This makes it possible that we delivered higher 
doses of FGF which, in vitro, can lead to a switch between induction and repression 
of myogenesis (Pizette et al., 1996). It is also possible that longer term exposure to 
FGF results in the upregulation of negative regulators of FGF signalling such as 
Sprouty or MAPK phosphatases (Eblaghie et al., 2003; Ozaki et al., 2001; Smith et 
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al., 2005) which could also lead to the discrepancy between these results and those 
we observe.  
Another potential candidate is FGF10 which is expressed in the limb bud 
mesenchyme (Ohuchi et al., 1997) but this has been shown not to induce 
myogenesis in vivo (Ward et al., 2003) and does not signal through FGFR4 (Zhang et 
al., 2006). Based on the combination of its expression in the limb bud mesenchyme 
(Fig.1 and (Ohuchi et al., 2000), and its ability to signal through FGFR4 (Ellsworth et 
al., 2002; Xu et al., 2000) we identified FGF18 as a candidate inducer of limb bud 
myogenesis although our data does not rule out contributions from other FGFs in 
inducing limb mud myogenesis. 
One observation from our data is that myogenic induction in these manipulations was 
mostly observed proximal to the bead. Although this might seem to conflict with our 
model, which would predict that myoblasts in the proximal limb bud should be more 
resistant to myogenic induction than more distal cells, this can be explained by the 
position of the myoblasts within the limb bud at these stages. Using Pax3 in situ 
hybridisation to label these migratory cells shows that the majority of myoblasts at 
HH 20/21 are found proximal to the position of grafted beads (Fig.6C). Therefore it is 
no surprise that we detect the strongest response in this region of the limb. In 
addition myogenic cells introduced into the distal region of the limb bud show 
reduced myogenesis. Therefore it is also likely that signals in the distal limb are also 
operating to supress muscle gene expression (Robson and Hughes, 1996). This 
could also explain why, in normal limb buds, myogenesis is seen first in the proximal 
then distal limb while our model, with proximal RA repressing and distal FGF18 
inducing muscle gene expression, would predict the opposite. Combining our 
observations with the previous data showing that the distal limb can repress 
myogenesis resolves this conflict. There are many signalling molecules in the limb 
bud which have been shown to inhibit myogenic gene expression such as BMPs 
(Amthor et al., 1998), Notch (Delfini et al., 2000), HGF/SF (Scaal et al., 1999) and 
Shh (Duprez et al., 1998) and it is likely that interactions between RA, FGF18 and 
these repressive factors are also important for myoblast differentiation.  
We also observe that in later manipulations loss of MyoD expression is seen in the 
dorsal but not the ventral muscle mass. Although it may be the case that the dorsal 
and ventral muscle masses are responding differently to the inhibitors we use, as 
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they do to Shh signalling (Anderson et al., 2012; Hu et al., 2012), it is also possible 
that this merely reflects the dorsal position of the bead following grafting. 
FGF18 induced MyoD expression requires ERK signalling 
Our data show that FGF18 beads induce phosphorylation of ERK MAP Kinase within 
one hour and that blocking this with the MEK inhibitor U0126 prevents ectopic MyoD 
expression. Similarly we show that U0126 can inhibit the onset of endogenous MyoD 
expression. However blocking ERK signalling over longer time scales does not inhibit 
MyoD and after a 24h incubation with U0126 beads manipulated limbs have similar 
MyoD expression to contralateral controls. It is possible that in these embryos the 
inhibitor is no longer active after this period of time or that induction of MyoD by 
FGF18 is regulating the timing of onset of MyoD expression rather than being 
absolutely required for myogenesis. Interestingly in FGF18 null mice skeletal 
development is also delayed but not abrogated (Liu et al., 2007) suggesting that the 
regulation of timing of differentiation may be a conserved feature of FGF18 function 
although muscle defects in this mouse have not been reported. In contrast long term 
effects on myogenesis are seen following grafts of the irreversible FGFR inhibitor 
FIIN 1 hydrochloride. This could reflect different stability of these inhibitors in vivo or 
it is possible that there are multiple phases of FGF signalling that are differently 
affected by these drugs. In this scenario U0126 can block the initial induction of 
MyoD through the ERK pathway but later induction is driven by FGF signalling 
through an alternative signalling pathway. 
Interactions between FGF18 and retinoic acid control timing of MyoD 
One striking feature of our data are the different temporal responses of Myf5 and 
MyoD to FGF18 beads. Myf5 is upregulated in early limb bud stages while MyoD is 
only induced prematurely after HH21; however this can be overcome by co-grafting 
FGF18 beads adjacent to beads soaked in BMS493, an antagonist of retinoic acid 
signalling. This implies that retinoic acid, which is synthesised in the embryonic flank, 
prevents premature differentiation of myoblasts as they migrate into the limb. As the 
limb bud expands they move away from the RA producing flank and towards the 
distal limb which expresses FGF18 as well as retinoic acid catabolising genes such 
as CYP26B1 (Reijntjes et al., 2003). Therefore we propose a model where the timing 
of limb myoblast differentiation is controlled by these opposing activities with high 
levels of RA in the proximal limb bud maintaining a proliferative myoblast pool while 
FGF18 and lower levels of RA in the distal limb promote MyoD expression and 
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differentiation (see Fig.6). The possibility that high concentrations of RA inhibit 
myogenesis while lower ones promote it (Reijntjes et al., 2010) could also help 
explain the proximal Ð distal direction of myogenesis, especially when combined with 
a distal inhibitory signal. Interestingly, a similar two signal model of opposing RA and 
FGF gradients has been proposed to pattern the proximal-distal limb axis in chicken 
embryos (Cooper et al., 2011; Mercader et al., 2000; Rosell-Dez et al., 2011) 
although work in mice has challenged this view (Cunningham et al., 2013). 
Differential responses of MRFs to FGF18 
Although our data show that FGF18 can induce both Myf5 and MyoD it is not clear if 
these are independently regulated or if MyoD is downstream of Myf5 given that Myf5 
can induce MyoD expression in chicken (Delfini and Duprez, 2004; Sweetman et al., 
2008) and mouse (Relaix et al., 2013) embryos. It is possible that the developmental 
delay before migrating myoblasts are competent to respond to FGF18 and 
upregulate MyoD is due to a requirement for Myf5. If this is the case this could 
explain why Myf5 can be induced by FGF18 at HH19 but MyoD is not. 
However while Myf5 is expressed before MyoD in chick limbs there is only partial 
overlap of these two genes (Delfini et al., 2000). It is also clear from genetic ablation 
experiments in mice that there are Myf5 independent muscle cell lineages (Gensch et 
al., 2008; Haldar et al., 2008) but not MyoD independent ones (Wood et al., 2013) 
while cell labelling and culture experiments have also suggested that at least two 
distinct populations of cells contribute to limb myogenesis (Kablar et al., 2003; Picard 
and Marcelle, 2013). It may be the case that the different temporal responses we 
observe in these assays are a result of distinct precursor populations of myoblasts in 
the developing limb. If so then we would expect to see Myf5 negative cells in the limb 
which respond to FGF18 by expression of MyoD. 
An alternative explanation is that the transcriptional regulation of MyoD is more 
sensitive to RA mediated repression than Myf5. In this case ERK activation at HH19 
can induce Myf5 but in these cells MyoD expression is not induced because the 
influence of RA at this time is still too strong, possibly because of interactions 
between RA and ERK response elements in the MyoD regulatory regions. 
Distinguishing between these possibilities will provide important insights into the 
mechanisms of cell fate determination. 
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Figure 1: Expression of FGF18 during limb development is consistent with a role in 
myogenic differentiation.  
(A) At HH18 FGF is expressed in the isthmus, pharyngeal arches, nasal placode and 
tailbud. (B) FGF18 is first detected in limbs at HH20 where is expressed in the distal 
mesenchyme of the limb bud. (C, D) FGF18 expression is maintained in the distal 
mesenchyme of the limb bud at HH22 and HH24 and (E) at HH26 is also detected in 
the condensing cartilage of the zeugopod. (F) section through developing forelimb at 
HH22 showing expression of FGF18 in the distal mesenchyme adjacent to the dorsal 
and ventral muscle masses shown be expression of Pax3 (G), Myf5 (H) and MyoD (I). 
fl, forelimb; hl, hindlimb; pa, pharyngeal arches; np, nasal placode; tb, tailbud; i, 







Figure 2: FGF18 induces MRF expression in limb buds in vivo. 
 
FGF18 beads grafted into developing limbs in ovo at HH19 induce Myf5 expression 
(B) but not MyoD expression (D) after 6 hours incubation. Unmanipulated 
contralateral limbs from the same embryos are shown in (A) and (C). FGF18 beads 
grafted into developing limbs in ovo at HH21 induce both Myf5 expression (H) and 
MyoD (J) expression after 6 hours incubation. Unmanipulated contralateral limbs 
from the same embryos are shown in (G) and (I). FGF18 beads grafted into 
developing limbs in ovo at HH21 do not induce myogenin after 6h incubation (F) but 
do after 24h (L). Unmanipulated contralateral limbs from the same embryos are 
shown in (E) and (K). 
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Transverse sections of Myf5 stained embryos grafted with FGF18 beads at HH19 (M) 
and HH21 (N) (positions of beads shown by dotted circles) show expression of Myf5 
in migrating myoblasts from hypaxial somites. FGF18 beads grafted into developing 
limbs in ovo at HH21 does not obviously alter Pax3 expression in wholemount in situ 
hybridisation (O) but in transverse sections localised downregulation of Pax3 is seen 
close to the FGF18 bead (P). 
Beads soaked in FGF4 induce MyoD expression when grafted at HH21 (Q) but 
FGF10 soaked beads do not (R). 
Beads soaked in 0.1%BSA do not induce Myf5 expression when grafted at HH19 (T). 
BSA beads grafted at HH21 do not induce Myf5 (V) or MyoD (X) expression. 
Unmanipulated contralateral limbs from the same embryos are shown in (S), (U) and 
(W). Dotted lines show outlines of limb buds. Arrows indicate ectopic MRF 





Figure 3: FGF18 beads induce ERK phosphorylation. 
 
FGF18 (A, B, C) beads, grafted into HH21 limb buds and incubated for 1 hour induce 
ERK phosphorylation. FGF10 (D, E, F) or 0.1% BSA (G, H, I) beads do not induce 
ERK phosphorylation. A, D, G: brightfield images, B, E, F: immunostaining with 






Figure 4: Inhibition of FGF receptors and MEK blocks FGF18 induced ectopic MyoD 
expression in forelimbs but MEK inhibition does not affect long term induction of 
endogenous MyoD. 
  
FIIN hydrochloride (A) or U0126 (B) beads grafted adjacent to FGF18 beads at HH21 
block induction of ectopic MyoD while beads soaked in LY294002 (C), SU5402 (D) or 
DMSO (E) do not. Embryos grafted with beads U0126 at HH23 and harvested after 
6h show reduced MyoD expression (G) compared to unoperated contralateral limbs 
(F) while control beads soaked in DMSO do not (H, I). Embryos grafted with FIIN 1 
hydorochloride beads at HH21 and harvested after 24h at HH26 show reduced MyoD 
expression (K) compared to contralateral control limbs (J). Beads soaked in U0126 (L, 
M) or DMSO (N, O) do not affect MyoD expression. Asterisks marks position of 




Figure 5: ATRA signaling interacts with FGF18 induced MyoD expression.  
 
ATRA beads grafted into forelimbs at HH21 and incubated for 24h (B) reduce 
endogenous MyoD expression compared to unmanipulated contralateral control 
limbs (A). Limbs grafted with both FGF18 and ATRA do not show ectopic MyoD 
expression (C, D). Forelimbs at HH19 with both FGF18 and BMS493 beads grafted 
for 6h show ectopic induction of MyoD (F) compared to contralateral control limbs (E) 
while HH19 limb grafted with BMS493 alone (G) or DMSO (H) do not show ectopic 







Figure 6: Model of FGF and Retinoic acid interactions regulating limb bud 
myogenesis.  
 
A) At HH 20, prior to MyoD expression, myoblasts expressing Pax3 are migrating 
from the ventro-lateral dermomyotome into the limb bud. RALDH in the flank 
generates retinoic acid in the proximal limb that represses MyoD expression. B) At 
HH23 myoblasts have migrated further into the limb, away from the source of RA, 
and the FGF18 expression domain in the distal limb has expanded allowing 
downregulation of Pax3 and induction of MyoD by FGF18 while inhibitory signals 
prevent premature MyoD expression in the distal limb bud. C) In situ hybridization for 
Pax3 at HH21 shows the position of migrating myoblasts in the proximal limb bud. 
The position of grafted FGF beads is shown by the white circle. 
 
 
